EXTRAWELL PHAR (00858): Guo Yi has been appointed as Chief Executive Officer.
China Pioneer Pharma Holdings (00858) announced that, in order to achieve clear division of responsibilities, meet the needs of the company's development, and enhance corporate governance, starting from January 1, 2026: (1) Dr. Xie Yi will resign as the company's CEO to focus on formulating company strategy. Dr. Xie will continue to serve as the chairman of the board and executive director after resigning as CEO; and (2) Dr. Guo Yi, an executive director, will be appointed as the new CEO.
EXTRAWELL PHAR (00858) announced that, in order to achieve division of labor, meet the needs of company development, and enhance corporate governance level, starting from January 1, 2026: (1) Dr. Xie Yi will resign as the Chief Executive Officer of the company in order to focus on formulating company strategies. Dr. Xie will continue to serve as the Chairman of the Board and Executive Director after resigning as CEO; and (2) Dr. Guo Yi, Executive Director, will be appointed as the new Chief Executive Officer.
Related Articles
DAIDO GROUP (00544) plans to establish a joint venture in the United States to acquire two data centers.
YUEXIUTRANSPORT (01052) November revenue from toll fees on the North Second Ring Expressway in Guangzhou was RMB 92.925 million, a decrease of 1.4% year-on-year.
CIRTEK HLDGS(01433) sold 620,000 shares of inventory on December 30th.
DAIDO GROUP (00544) plans to establish a joint venture in the United States to acquire two data centers.
YUEXIUTRANSPORT (01052) November revenue from toll fees on the North Second Ring Expressway in Guangzhou was RMB 92.925 million, a decrease of 1.4% year-on-year.
CIRTEK HLDGS(01433) sold 620,000 shares of inventory on December 30th.
